This section contains press releases and other materials from third parties (including paid content). The Globe and Mail has not reviewed this content. Please see disclaimer.

Analysts’ Top Healthcare Picks: Incyte (INCY), Zevra Therapeutics (ZVRA)

Tipranks - Tipranks - Wed Jun 10, 6:20AM CDT

There’s a lot to be optimistic about in the Healthcare sector as 3 analysts just weighed in on Incyte (INCY), Zevra Therapeutics (ZVRA) and Biomea Fusion (BMEA) with bullish sentiments.

Introducing TipRanks MCP for Agents

Incyte (INCY)

In a report released today, Allison Bratzel from Piper Sandler maintained a Buy rating on Incyte, with a price target of $110.00. The company’s shares closed last Monday at $100.64.

According to TipRanks.com, Bratzel is a 5-star analyst with an average return of 37.5% and a 56.0% success rate. Bratzel covers the Healthcare sector, focusing on stocks such as Ultragenyx Pharmaceutical, Abivax SA Sponsored ADR, and BioMarin Pharmaceutical. ;'>

Incyte has an analyst consensus of Moderate Buy, with a price target consensus of $110.06, implying a 7.1% upside from current levels. In a report released yesterday, TipRanks – Anthropic also upgraded the stock to Buy with a $114.00 price target.

See today’s best-performing stocks on TipRanks >>

Zevra Therapeutics (ZVRA)

In a report released today, Sumant Kulkarni from Canaccord Genuity reiterated a Buy rating on Zevra Therapeutics, with a price target of $29.00. The company’s shares closed last Monday at $12.09.

According to TipRanks.com, Kulkarni is a 4-star analyst with an average return of 7.7% and a 45.6% success rate. Kulkarni covers the Healthcare sector, focusing on stocks such as MapLight Therapeutics, Inc., ACADIA Pharmaceuticals, and Definium Therapeutics. ;'>

Zevra Therapeutics has an analyst consensus of Strong Buy, with a price target consensus of $26.00, which is a 142.8% upside from current levels. In a report released yesterday, Cantor Fitzgerald also maintained a Buy rating on the stock with a $34.00 price target.

Biomea Fusion (BMEA)

In a report released today, Edward Tenthoff from Piper Sandler reiterated a Buy rating on Biomea Fusion, with a price target of $7.00. The company’s shares closed last Monday at $1.15.

According to TipRanks.com, Tenthoff is a 3-star analyst with an average return of 1.5% and a 36.6% success rate. Tenthoff covers the Healthcare sector, focusing on stocks such as CAMP4 Therapeutics Corporation, Arrowhead Pharmaceuticals, and Milestone Pharmaceuticals. ;'>

Biomea Fusion has an analyst consensus of Moderate Buy, with a price target consensus of $7.20, implying a 490.2% upside from current levels. In a report issued on June 3, H.C. Wainwright also maintained a Buy rating on the stock with a $4.00 price target.

Read More on INCY:

Disclaimer & DisclosureReport an Issue

This article contains syndicated content. We have not reviewed, approved, or endorsed the content, and may receive compensation for placement of the content on this site. For more information please view the Barchart Disclosure Policy here.

All market data (will open in new tab) is provided by Barchart Solutions. Copyright © 2026.

Information is provided 'as is' and solely for informational purposes, not for trading purposes or advice. For exchange delays and terms of use, please read disclaimer (will open in new tab).